Clinical trial NCT02735694: Cycloserine in the Treatment of Sleep Apnea
Official title: Cycloserine in the Treatment of Sleep Apnea
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Sleep Apnea Syndromes
Keywords: Sleep apnea
Hypoglossal Nerve
N-methyl-D-aspartate receptors
Cycloserine
Short-term potentiation
Lead sponsor: University of Manitoba
Sponsor class: OTHER
Collaborators: name: University of Calgary
First posted: 2016-04-13
Enrollment: 18
Sex: ALL
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study is being conducted to determine whether cycloserine is effective for the treatment of sleep apnea. Cycloserine is an antibiotic that has been extensively used in the treatment tuberculosis. However, more recently it was shown to enhance memory responses. Cycloserine may enhance the response of respiratory muscles to apnea and potentially reduce the severity of sleep disordered breathing.

Detailed description: The passive human upper airway (UA) is a collapsible tube with a relatively high compliance. At atmospheric luminal pressure, its cross-sectional area varies considerably. Subjects in whom the pharynx is closed, or nearly closed, at near atmospheric pressure require an upper airway dilating force to maintain adequate ventilation. During wakefulness pharyngeal dilator muscles (dilators) provide the necessary force to permit an adequate flow, regardless of how collapsible the pharynx is. This dilator activity is substantially lost at sleep onset. Subjects in whom the passive UA cannot permit adequate ventilation must recruit dilators through reflex mechanisms if they are to remain asleep. Recent studies have shown that activation of the muscles that open the airway in the course of obstructive apneas persists to a variable degree after the relief of obstruction, evidencing the presence of memory for prior activation in the the brain centers that supply the dilator muscles.

Short-term potentiation (STP) is a neuro-physiological mechanism that results in a time-dependent increase in motor activity, that is not explainable by changes in stimulus intensity, and which persists after disappearance of the stimulus ( "after-discharge"). STP is well documented in diaphragmatic responses to chemical stimuli. Prominent STP in upper airway muscles would promote a stronger dilator response to upper airway occlusion. The after-discharge would also help to maintain dilator activity following the ventilatory phase of obstructive events, thereby mitigating recurrence of obstruction. Patients with obstructive sleep apnea (OSA) vary greatly in the extent to which this memory or STP is present. The investigators postulate that interventions that could potentiate the development of memory for prior activation would mitigate the recurrence of apneas and reduce the severity of obstructive sleep apnea. The same interventions, those that enhance memory for prior activation, would also likely improve central apneas in that these apneas represent loss of diaphragm activity following hyperventilation. Memory for prior activation of the diaphragm has been well documented in the past and appears to be defective in such patients.

There has been extensive research into methods of improving neural memory. Cycloserine, an antibiotic that has been, and continues to be, used extensively in the treatment of drug-resistant tuberculosis, was shown to be effective in promoting memory in small doses (much less than those used for tuberculosis) both in animals and humans. We, therefore, propose that cycloserine has the potential of enhancing the memory properties of neurones supplying pharyngeal muscles and propose to study the effect of using it on the severity of sleep apneas of the obstructive and central varieties.

Patients who have been diagnosed with OSA following routine clinical sleep studies will be asked to participate. Participation involves agreeing to two additional full night studies in the sleep laboratory, separated by 1 week. Both studies will be identical to the routine clinical studies, except that the patient will be asked to swallow a capsule containing either placebo or 250 mg cycloserine 1 to 2 hours prior to going to sleep. The order of the Placebo and Test nights will be randomized. The patient will be monitored continuously by a dedicated, senior polysomnography technologist.

Eligibility criteria: Inclusion Criteria:

* Moderate to severe obstructive or central sleep apnea (Apnea Hypopnea Index \> 30/hr).
* Minimum Oxygen saturation during respiratory events \>70% throughout sleep during the clinical sleep study.

Exclusion Criteria:

* Contraindication to the use of cycloserine, namely history of allergy to cycloserine, seizures, depression, severe anxiety or psychosis, excessive use of alcohol or renal failure.
* Past or current history of tuberculosis
* Hypercapnia \> 55 millimeters of mercury during the diagnostic clinical sleep study.
* Neuromuscular disease.
* Obesity-hypoventilation syndrome.
* Pregnancy.
* Significant co-morbidities: Dialysis-dependant renal failure, severe asthma or chronic lung disease, congestive heart failure, previous stroke.
* Recent (within 3 months) myocardial infarction or Active coronary ischemia event.

Primary outcomes:
measure: Change in Apnea-hypopnea index (AHI)
timeFrame: Baseline and one week
Secondary outcomes:
measure: Improvement in total sleep time
timeFrame: Baseline and one week
measure: Improvement in average oxygen saturation
timeFrame: One week
Other outcomes:
measure: Improvement in the awakening and arousals index
timeFrame: One week
Locations:
city: Calgary
country: Canada
facility: University of Calgary
state: Alberta
city: Winnipeg
country: Canada
facility: Sleep Disorders Centre
state: Manitoba
Study officials:
affiliation: University of Manitoba
name: Magdy K Younes, Md, PhD
role: PRINCIPAL_INVESTIGATOR
References: